Intercept Pharmaceuticals Total Revenue

Intercept Pharmaceuticals (ICPT) currently reports a total revenue of $290M as of September 2023. That compares with $330M in the prior-year period — down 12.7% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Intercept Pharmaceuticals's total revenue history and peer comparisons.

Intercept Pharmaceuticals's total revenue decreased from $330M to $290M — a 12.7% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intercept Pharmaceuticals's total revenue of $290M is lower than the Healthcare sector average of $110B. That is roughly 99.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Intercept Pharmaceuticals reported $290M in total revenue as of September 2023. That compares with $330M in the prior-year period — down 12.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $290M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Intercept Pharmaceuticals, and consider following ICPT for alerts when major investors trade the stock.